Lucid Diagnostics to join Russell 2000, Russell 3000 indexes
TipRanks
May. 27, 2025, 05:35 AM
Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced that the company will join the small-cap Russell 2000 Index and the broad-market Russell 3000 Index, effective after the close of U.S. equity markets on June 27, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
Disclaimer & DisclosureReport an Issue
- Lucid Diagnostics director buys $457.6K in common stock
- Lucid Diagnostics files to sell 36.98M shares of common stock for holders
- Lucid Diagnostics Reports Increased Losses Amid Revenue Decline
- Anticipated Medicare Coverage and Strategic Positioning Drive Buy Rating for Lucid Diagnostics
- Lucid Diagnostics: Strong Cash Position and Growing EsoGuard Test Volumes Justify Buy Rating
